The Highly Selective 5-HT_2B Receptor Antagonist MW073 Mitigates Aggressive Behavior in an Alzheimer's Disease Mouse...

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive neurodegeneration and synaptic dysfunction.
• Neuropsychiatric syndromes, including aggression, affect 40-60% of AD patients, increasing caregiver burden.
• Elevated serotonin 5-HT2B receptor levels are observed in the AD brain.

Purpose of the Study:

• To investigate the therapeutic potential of the selective 5-HT2B receptor antagonist MW073.
• To evaluate the effects of MW073 on aggressive behavior in a mouse model of Alzheimer's disease.

Main Methods:

• Tg2576 mice, an established model for AD amyloid pathology, were used.
• MW073 was administered to assess its impact on aggressive behavior in a resident-intruder assay.
• Behavioral changes were quantified to determine treatment efficacy.

Main Results:

• MW073 treatment significantly decreased aggressive behavior in male Tg2576 mice.
• The study demonstrated a clear reduction in aggression following MW073 administration.
• No significant adverse effects were mentioned in the provided text.

Conclusions:

• Serotonin 5-HT2B receptor signaling plays a role in the neuropsychiatric symptoms of Alzheimer's disease.
• MW073 shows promise as a potential treatment for aggression and behavioral dysfunction in AD.
• Targeting 5-HT2B receptors may offer a novel therapeutic strategy for managing cognitive and behavioral deficits in AD.